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Abstract
Background: Group B Streptococcus (GBS) is a leading cause of serious infection in very young infants. Robust
incidence data from many geographic regions, including Latin America and Asia, are however lacking.
Methods: A multicenter, hospital-based observational study was performed in Panama, Dominican Republic, Hong
Kong and Bangladesh. All represented urban, tertiary referral hospitals, except Bangladesh. GBS cases
(microbiological isolation from normally sterile sites in infants aged 0–89 days) were collected over 12 months.
Results: At 2.35 (95 % CI: 1.74–3.18) cases per 1000 live births, the incidence of early onset GBS disease (EOD) was
highest in the Dominican Republic, compared with 0.76 (95 % CI: 0.41–1.39) in Hong Kong and 0.77 (95 % CI: 0.44–1.35)
in Panama, while no cases were identified in Bangladesh. Over 90 % of EOD cases occurred on the first day of life, with
case fatality ratios ranging from 6.7 % to 40 %, varying by center, age of onset and clinical presentation. Overall, 90 %
of GBS (EOD and late onset disease) was due to serotypes Ia, Ib and III.
Conclusions: The incidence rate of early onset GBS infection reported in Dominican Republic was not dissimilar from
that described in the United States prior to screening and intrapartum antibiotic prophylaxis, while the incidence in
Hong Kong was higher than previously reported in the Asian region. The failure to identify GBS cases in Bangladesh
highlights a need to better understand the contribution of population, healthcare and surveillance practice to variation
in reported incidence. Overall, the identified disease burden and serotype distribution support the need for effective
prevention methods in these populations, and the need for community based surveillance studies in rural areas where
access to healthcare may be challenging.
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Background
Group B Streptococcus (GBS) or Streptococcus agalac-
tiae is a significant cause of serious infections in neo-
nates, manifesting as sepsis, pneumonia and meningitis.
GBS is commonly identified in rectal and vaginal cul-
tures of women who are colonized, a recognized risk fac-
tor for perinatal infection [1]. Infant GBS infection
occurs as a continuum over the first 3 months of life,
but has often been categorized as early-onset disease
(EOD; occurring between birth and 6 days of age) or
late-onset (LOD; occurring between 7 and 89 days of
age) [1]. Five of nine capsular serotypes, III, Ia, V, Ib and
II, cause 95 % of invasive disease (in decreasing fre-
quency) [2].
A recent meta-analysis of published studies reported a
mean global incidence of 0.53 per 1000 live births (LB),
with a range from 0.02 per 1000 LB in Southeast Asia to
1.21 per 1000 LB in Africa (data primarily from South-
ern and Eastern Africa). Incidence data from Asia were
based on relatively few studies [2]. Such variation may
reflect differences in study methodology (specifically, in
case ascertainment and laboratory diagnostics), anti-
biotic usage, health care access or possibly regional
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population differences [3]. The wide variation in the re-
ported perinatal GBS incidence contrasts with the more
consistent reported rates of maternal GBS colonization
[4]. This incongruity mandates a strong focus on case
detection methodology in prospective surveillance
studies.
Where implemented, administration of intrapartum anti-
biotic prophylaxis (IAP) to mothers at risk of delivering
GBS-infected infants (defined by maternal colonization or
specified clinical risk factors) has reduced but not elimi-
nated EOD, and has had no effect on LOD [5–7]. Imple-
mentation of IAP remains difficult in resource-constrained
regions due to logistics and cost, and requires routine ac-
cess to healthcare. A maternal vaccine against serotypes Ia,
Ib and III is also in development [8]. Robust global data
demonstrating the incidence and serotype distribution of
GBS infection in young infants will be invaluable to under-
stand the potential impact of these preventive measures [9].
The current observational study evaluated the incidence,
serotype distribution and case fatality ratio (CFR) of inva-
sive GBS disease in infants <3 months in three hospitals in
Latin America and two hospitals in Asia, where few data
currently exist.
Methods
Study design and setting
This was an observational, multi-center study performed
in five hospitals in four countries (Panama, Dominican
Republic [two hospitals], Hong Kong, Bangladesh). All
study hospitals were large urban referral centers except
in Bangladesh where the facility was a rural, not-for-
profit private hospital). Study hospitals offered maternity
services, for both low and high risk pregnancies with
skilled attendants, as well as pediatric services. The ex-
ception was in Dominican Republic where two hospital
centers participated: the first provided maternity and
neonatal services only and the second provided pediatric
services. The hospitals were within close proximity of
each other serving the same catchment population.
The study hospital in Panama was a large maternity hos-
pital in the capital city with 15000 births per year. Infants
developing signs and symptoms of sepsis were immedi-
ately referred to the national pediatric reference hospital
which was directly adjacent to the maternity hospital. The
first hospital center in Dominican Republic served as the
national reference for maternal medicine with 18000 de-
liveries per year. Although, neonatal intensive care ser-
vices were available on site; the hospital had no pediatric
services. A second hospital, offering pediatric and neonatal
services for the same catchment population in the capital,
therefore participated to ensure the capture of GBS LOD
cases presenting post maternal discharge. The site in
Hong Kong included public hospitals that offered obstet-
ric, neonatal and pediatric services for a densely populated
urban area with a catchment of 1.3 million inhabitants
with 13000 deliveries per year. Over 90 % of births occur
in hospital in Panama, Dominican Republic and Hong
Kong.
The study hospital in Bangladesh was one of two hos-
pitals serving the rural sub-district of Mizapur in
Bangladesh. It is a private, not for profit hospital with
both obstetric and pediatric services and 8000 deliveries
per year. Previous studies reported that only 25 % of
births in the Mirzapur region occur in hospital [10].
All study centers implemented risk-based screening
for GBS as standard of care: mothers presenting in labor
with clinical risk factors associated with increased risk of
GBS disease in the infant (e.g., maternal fever, prolonged
rupture of the membranes) were administered intraven-
ous antibiotic prophylaxis.
The study protocol was approved by local ethics
committees and conducted in compliance with Good
Pharmacoepidemiological Practice, local regulations
and the Declaration of Helsinki (2008). This study was
approved by the following ethics committees: the Comite
de Bioetica en la Investigacion del Hospital del Niño and
the Comite Nacional de Bioetica en la Investigacion del
Instituto conmemorativo Gorgas de Estudios de la Salud
in Panama, the Comite de Bioetica del Hospital Materni-
dad Nuestra Señora de la Altagracia and the Comite de
Etica y de Investigaciones Fundacion Dominicana de
Infectologia, Inc in Dominican Republic, the Joint Chinese
University of Hong Kong – New Territories East Cluster
Clinical Research Ethics Committee and the Ethical Re-
view Committee of the Bangladesh Institute of Child
Health.
Written informed consent was obtained from the par-
ents/guardians of all subjects. The informed consent was
countersigned by the personnel who had conducted the
informed consent discussion who was qualified accord-
ing to local regulations.
Study population
Infants aged 0 to 89 days, were enrolled into the study
following microbiological confirmation of GBS by a posi-
tive culture from a sterile site (blood, cerebrospinal fluid,
lung aspirate, joint fluid) according to local laboratory
procedures, and informed consent from the legal parent/
guardian (Enrolled Population). Sterile site cultures were
routinely performed, according to local standards, on all
infants admitted with clinical signs and symptoms of
sepsis, meningitis or pneumonia. Enrollment was pri-
marily prospective at the time of diagnosis. Given the
rare primary outcome, retrospective enrollment was per-
mitted by the protocol. Infant follow up was from the
time of enrolment until the first of hospital discharge,
death or withdrawal from the study. The study duration
Rivera et al. BMC Pediatrics  (2015) 15:143 Page 2 of 9
(enrollment period) was 12 months at each study
hospital.
Data collection and laboratory methods
Data concerning subject demographics, birth and disease
characteristics, disease outcome, maternal and infant anti-
biotic use were extracted from medical records and/or par-
ental/guardian interviews following subject enrollment.
The microbiological confirmation of GBS followed local
standards, though all centers used automated (BacT/
Alert®; Biomerieux, France or BACTEC®; Becton Dickin-
son, United States) enrichment culture methods. Sus-
pected Group B Streptococcus colonies were confirmed
using Gram stain and GBS antigen latex agglutination
testing or biochemical (Christie Atkinson Munch-
Petersen, aesculin bile) testing. Serotyping of recovered
GBS isolates was performed using the Strep-B-Latex™
(Statens Serum Institut, Denmark) rapid latex agglutin-
ation test [11] in one central laboratory (The Respiratory
and Meningeal Pathogens Research Unit, Johannesburg,
South Africa).
Sample size
As an observational, descriptive study with no a priori hy-
pothesis, there was no pre-defined sample size. However,
the precision of incidence estimates depended on the
underlying GBS incidence and birth cohort size. If five
GBS cases were observed among 10,000 births, the point
incidence estimate would be 0.5 per 1000 LB with a 95 %
confidence interval (CI) of 0.16 to 1.17 per 1000 LB. For
the same incidence, a birth cohort of 20,000 LB would
give increased precision with a narrower 95 % CI of 0.24
to 0.92 per 1000 LB.A birth cohort of 5,000 would give re-
duced precision with a 95 % CI of 0.05 to 1.44 per 1000
LB. The annual birth cohort within the study varied from
4,227 in Bangladesh, to 17,867 in Dominican Republic.
Statistical methods
To be eligible for analysis (Analysis Population), enrolled
infants were required to be born in the study hospital (all
centers with maternity unit) or within the catchment area
for the study hospital (centers without a maternity unit).
Demographics and baseline characteristics of the Analysis
Population were summarized descriptively using the mean
(standard deviation) or median (range) for continuous var-
iables and the frequency distribution for categorical vari-
ables. The incidence rate was expressed as rate per 1000
live births (LB), and computed for each hospital center
i ¼ total n of cases admitted from study start to 12 monthstotal n of live births from study start to 12 months  1 000
n o
.
Denominators for incidence calculation used: (i) the
in-hospital birth cohort for centers with a maternity
unit, or (ii) the number of LB occurring in the commu-
nity catchment area of the hospital for non-maternity
centers. Serotype distribution was described for the Ana-
lysis Population as a frequency distribution (number and
percentage of participants) for EOD, LOD and total
cases. The case fatality ratio (CFR) was expressed as the
percentage (%) of GBS cases in the Analysis Population
who died due to GBS invasive disease within the study
period. The Wilson score interval method was used to
calculate all 95 % CI [12]. All analyses were completed
using SPSS version 20.
Results
Characteristics of study population
Of the 108 participants enrolled with GBS culture con-
firmed disease, 93 met pre-defined eligibility criteria and
were included in analyses (Analysis Population) (Fig. 1).
Of the 15 exclusions, 10 were born outside the study
hospital and five resided outside the study catchment
area. Bangladesh did not identify any GBS cases over the
study period.
Group B streptococcus was isolated from blood or
CSF cultures in all but one case. A single case from
Hong Kong had GBS isolated from both blood and joint
fluid samples.
The Analysis Population (Table 1) represented diverse
ethnic and racial origin groups reflecting the different
geographic regions. The lowest mean birth weight was
reported in Dominican Republic (2533 g) which may re-
flect the relatively high prematurity rate (40 %) and cap-
ture of high risk pregnancies through an obstetric
referral center (Table 1).
All study hospitals offered risk based screening for GBS
rather than systematic screening for colonization in late
pregnancy. A subset of GBS cases were born to mothers
recognized as at clinical risk of GBS and subsequently
treated during delivery with IAP: 17 % and 10 % of GBS
cases from Dominican Republic and Panama, respectively
(Table 1). The most common indication for IAP was pro-
longed rupture of the membranes with intravenous ampi-
cillin most commonly prescribed. Without additional
information on the duration and dose of the intravenous
antibiotics administered, it is difficult to comment further
on the reasons underlying the failure of this intervention.
Between 92–100 % of EOD cases occurred in the first
48 h of life across all centers (Table 2). The distribution of
age at the time of LOD admission differed by center:
Hong Kong reported the lowest median and narrowest
range of age at LOD admission (14 days; range of 9–20
days) compared to centers in Latin America (median 26
and 32 days; range of 8–57 and 18–85 days, respectively
for Dominican Republic and Panama).
Incidence rate and case fatality ratio
The incidence of GBS varied across countries, but EOD
was consistently more frequent than LOD (Table 3).
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Table 1 Demographic and other baseline characteristics of the study population per study site and overall
Panama Dominican Republic Hong Kong Total
Site 1 Site 2
N 21 42 15 15 93
Males/females 11/10 22/20 6/9 5/10 44/49
Racial origin/Ethnicity
Asian/Chinese - - - 15 (100 %) 15 (16 %)
Black 2 (10 %) 16 (38 %) 1 (7 %) - 19 (20 %)
Caucasian - - - - -
Hispanic 18 (86 %) 26 (62 %) 14 (93 %) - 58 (62 %)
Other 1 (5 %)* - - - 1 (1 %)
Birth weight (grams)
Mean birth weight (SD) 2819 (719) 2533 (825) 2855 (654) 3234 (397) 2762 (753)
Median (Range) 2950 (740–3900) 2665 (907–3964) 2954 (1000–3636) 3250 (2220–3850) 2950 (740–3964)
Gestational age (weeks)
Mean gestational ageδ (SD) 38 (3) 37 (4) 38 (3) 39 (1) 37 (4)
Median (Range) 38 (25–41) 38 (26–42) 39 (27–42) 39 (37–41) 38 (25–42)
Premature (<37 wks) 5 (24 %) 18 (43 %) 1 (7 %) 0(0 %) 24 (26 %)
Premature 34-37wks 4 (19 %) 10 (24 %) 0 14 (15 %)
Very premature <34 weeks 1(5 %) 8 (19 %) 1 (7 %) 10 (11 %)
Mother intrapartum antibiotic administered
Yes 2 (10 %) 7 (17 %) - 1 (7 %) 10 (11 %)
No 17 (81 %) 35 (83 %) 15 (100 %) 14 (93 %) 81 (87 %)
Unknown 2 (10 %) - - - 2 (2 %)
Other = Indian (n = 1); δ gestational age is defined as gestational age at the time of delivery
Fig. 1 Participant distribution. Footnote: Four participants were retrospectively enrolled. EOD: Early Onset Disease; LOD: Late Onset Disease
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Excluding Bangladesh, where no cases were identified,
the incidences of EOD per 1000 births ranged from 0.76
(95 % CI: 0.41–1.79) in Hong Kong to 2.35 (1.74–3.18)
in Dominican Republic. The incidence of LOD ranged
from 0.17 (0.10–0.30) in Dominican Republic to 0.58
(0.31–1.10) in Panama. The highest case fatality rate
(CFR) for GBS cases was recorded in Dominican Repub-
lic and the lowest in Hong Kong (Table 3).
Although clinical signs and symptoms were not rou-
tinely collected within the study, review of GBS cases for
which both blood and CSF specimens are available for
the same individual can inform on clinical presentation;
a positive CSF culture indicating meningitis. Both Blood
and CSF cultures were available from 46 infants
(Table 4). The four fatalities among these 46 participants
were all associated with meningitis (three LOD in
Dominican Republic and one EOD in Hong Kong).
Serotype distribution
Overall, 91 % of all GBS cases were due to serotypes Ia,
Ib or III (87 % of all EOD; 100 % of all LOD; Fig. 2a).
Serotype III alone was responsible for 40 % of EOD
(Fig. 2b) and 85 % of LOD cases (Fig. 2c). Serotype dis-
tribution varied geographically. For EOD, serotype III
predominated in Dominican Republic (38 %), while sero-
type Ia was most common in Panama (50 %) and in
Hong Kong serotypes Ib and III were equally repre-
sented (40 % of disease each). For LOD, serotype III pre-
dominated in Panama and Dominican Republic (100 %
and 83 % of cases respectively), while serotype Ib
accounted for 40 % cases in Hong Kong. All fatal cases
were serotype III. The serotype distribution differed be-
tween the two Dominican Republic hospital as one (ma-
ternity) captured only EOD cases and the second
(pediatric) captured mainly LOD cases.
Discussion
This study confirms the importance of GBS infection as a
cause of early onset disease (EOD) in newborns. The inci-
dence reported in the Dominican Republic (2.35 EOD per
1000 LB) was similar to the highest incidence reported in
the literature from South Africa (2.0 per 1000 LB) [13, 14]
and to rates reported from the United States before uni-
versal screening and IAP implementation (1.80 per 1000
LB) [15, 16]. EOD incidence was three-fold lower in
Panama (0.76) and Hong Kong (0.77), while no cases were
found in Bangladesh. The incidence in Hong Kong was
higher than previous estimates from the Asian/Western
Pacific region [2] highlighting the importance of having
adequate clinical and microbiological diagnostics in place.
The range of incidence estimates by country also prompts
consideration of potential factors driving this variability.
The main risk factor for infant GBS disease is rectova-
ginal colonization of the mother during late pregnancy
[1]. The high incidence of EOD in Dominican Republic
may reflect the high reported prevalence (44 %) of ma-
ternal colonization in the population attending for deliv-
ery at study hospitals [17]. A lower maternal prevalence
has been reported in Asia (7.7 %–10.4 % in Bangladesh
and Hong Kong respectively [18, 19], though the limited
variation between maternal data from Bangladesh and
Hong Kong make it unlikely that colonization alone can
drive the differences in observed disease incidence.
Racial origin, reflecting genetic or behavioral differ-
ences, may also contribute to the variation in disease in-
cidence. Black racial origin is associated with higher
GBS disease incidence [20–22]. Approximately 40 % of
EOD cases in Dominican Republic were of black racial
origin reflecting the potential contribution of that risk
factor to disease incidence within that country setting.
However, Dominican Republic also reported the highest
proportion of preterm infants among GBS EOD cases
(40 %), another reported risk factor for GBS disease [23].
It remains difficult to tease apart the individual contri-
butions of these risk factors to overall disease incidence.
Case ascertainment is an important determinant of in-
cidence and can be driven by access to healthcare, clin-
ical practice and diagnostics [3]. Calculations for EOD
incidence were based on hospital in-born birth cohorts,
meaning all mothers had access to healthcare during the
period of greatest risk for EOD. Indeed, over 90 % of
EOD cases presented within the first 48 h of life across
all study centers emphasizing the importance of estab-
lishing hospital based surveillance in place during this
post-delivery period.
As an observational study, local clinical standards for
the investigation of suspected sepsis were followed
which may have introduced variation in case ascertain-
ment. Indeed, a previous systematic review of neonatal
sepsis etiology in developing countries reported a lower
Table 2 Age at admission of the study population per study site
Panama Dominican Republic Hong Kong Total
Site 1 Site 2
EOD (N) 12 42 3 10 67
Median age (days) at admission (range) % admitted in first 48 hrs 0 (0–3) 92 % 0 (0–2) 98 % 0 (0–3) 67 % 0 (0–0) 100 % 0 (0–3) 96 %
LOD (N) 9 N/A 12 5 26
Median age (days) at admission (range) 32 (18–85) N/A 25.5 (8–57) 14 (9–20) 20.5 (9–85)
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Table 3 Incidence rate of invasive group B streptococcal disease and case fatality ratio in the study population***
GBS incidence rate
Panama Dominican Republic* Hong Kong
Site 1 Site 2
EOD LOD Total EOD LOD EOD LOD Total
Observed GBS cases 12 9 21 42 12** 10 5 15
Live births 15 500 15 500 15 500 17 867 70 297 13 244 13 244 13 244
Incidence rate per 1 000 live births 0•77
(0•44–1•35)




Number of days hospitalized
Mean (SD) 11 (5) 9 (6) 6 (5) 16 (4)
Median (Range) 11 (0–16) 10 (0–39) 6 (0–13) 15 (8–24)
Case Fatality Ratio
EOD LOD Total EOD LOD Total EOD LOD Total EOD LOD Total
Deaths 2 1 3 9 - 9 1 5 6 1 0 1
Number of cases 12 9 21 42 - 42 3 12 15 10 5 15






















*An overall early and late onset disease (EOD and LOD) incidence rate for Dominican Republic was not calculated because Site 1 (maternity) used a hospital-based denominator and Site 2 (pediatric) used a
community-based denominator. **The three EOD cases recorded at Site 2 (pediatric) were not included in incidence calculations as cases were from different hospital birth cohorts without a clear denominator. ***











proportion of cases due to GBS in rural referral hospitals
versus maternity hospitals (1.0 % versus 6.6 % of neo-
natal cases, respectively) [24]. All centers in the current
study, other than Bangladesh, represented urban tertiary
maternity centers. However, it was beyond the scope of
the current study to directly assess the impact of clinical
practice on reported incidence. The ideal may be to sys-
tematically take cultures on all infants admitted to hos-
pital to further maximize case ascertainment, but this is
often not practical within routine care. Unfortunately,
data on the number of cultures taken during the study
were not routinely collected to ascertain the impact of
this aspect of clinical practice on case ascertainment.
The distribution of organisms causing neonatal sepsis at
a center may also indicate differences in clinical and hy-
giene practices. Zhaidi et al. found a preponderance of
Staphylococcus aureus and Gram negative organisms
causing neonatal sepsis in studies from Asia [24]. These
organisms are commonly thought to be environmentally-
acquired, raising concerns that poor hygienic practices
may mask vertically-acquired infections. The study center
in Bangladesh mirrored this pattern with Staphylococcus
aureus and Klebsiella pneumoniae being the most com-
monly isolated early infant pathogens (representing 2 % of
all cultured blood samples). Future studies would benefit
from a systematic description of all organisms found to re-
sponsible for neonatal sepsis to assess the potential impact
of hygiene practices within and across sites.
The observational nature of this study may also have
introduced variability through diagnostic and microbiol-
ogy practice. For example, despite general recommenda-
tions across all study hospitals to collect 1–2 mL of
blood for culture, blood volumes collected in infants
may have varied which can influence GBS isolation rates
[25]. In addition differences in antibiotic administration
rates could have differentially affected GBS culture
yields. Unfortunately, data on blood volumes and anti-
biotic administration were not routinely collected within
the current study to assess the possible impact.
GBS isolation rates are reported to be higher with auto-
mated versus manual culture methods, and with selective
Fig. 2 Serotype distribution by country and by center ((Analysis
Population) for all GBS cases (a) for early onset disease (b) and late
onset disease (c). Footnote: No late onset disease cases were recorded
at Site 1 in the Dominican Republic as this was a maternity without a
pediatric facility
Table 4 Case fatality ratio (%) by disease presentation and center for a study population subset with both blood and cerebrospinal
fluid cultures available (n = 46)
Case Fatality Ratio
Panama Dominican Republic Hong Kong
Site 1 Site 2
Bacteremia Meningitis Total Bacteremia Meningitis Total Bacteremia Meningitis Total Bacteremia Meningitis Total
Deaths 0 0 0 0 - 0 0 3 3 0 1 1
Number
of cases
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versus non-selective culture methods [3, 26]. All centers
used automated and enriched culture techniques which
should have limited the impact of diagnostics on reported
GBS incidence.
Reasons underlying the reported zero incidence of
GBS disease in Bangladesh could include absence of dis-
ease in the population, although one GBS case was iden-
tified after study end, differences in hygiene practice or
antibiotic usage leading to masking of GBS infection. As
this study considered a hospital born birth cohort that
remained in hospital for up to 3 days post-delivery, it is
unlikely that poor healthcare seeking behavior can ac-
count for lack of EOD case identification within the
study cohort. However, given the high proportion of
births that occur at home in the Mizapur region (75 %),
the study cohort may not be representative of the re-
gional birth cohort. Access and cost of healthcare may
have played a part in under-ascertainment of LOD cases.
The relatively small birth cohort, compared to other
study hospitals (up to 18,000 births) is reflected in the
uncertainty of the incidence estimate (Table 3) and indi-
cates a potential role of chance in the finding.
LOD rates were lower than EOD rates across all cen-
ters (0.17–0.58 vs 0.76–2.35 per 1000 LB). While this re-
flects the published literature [3] some under-estimation
of LOD remains likely: some infants may have moved
out of the hospital catchment area or presented to non-
study hospitals, particularly in the urban study areas
where a choice of pediatric services exists. Access to
healthcare post-delivery will also impact LOD case as-
certainment; most likely an issue in Bangladesh where
the study hospital was the only hospital within a rural
community. For infections that are fatal in the absence
of prompt treatment, delays in reaching healthcare ac-
cess would reduce case identification [10, 27].
Elsewhere, population movements may have led to an
under-estimation of LOD. It is known that women from
Haiti and the Chinese mainland may access delivery care
in Dominican Republic and Hong Kong, respectively.
Women returning to their homeland post-delivery will
likely result in failure to identify LOD cases in the study
cohort. Late onset disease incidence estimates based
upon community population denominators (Dominican
Republic) may also have under-estimated incidence. If
there is differential use of pediatric services across Santo
Domingo, perhaps for proximity reasons, it may not be
appropriate to use the catchment population from the
whole of city in incidence calculations. If one assumes
that only infants living in the same sub-district of Santo
Domingo as the study hospital presented with a sick in-
fant, the estimated incidence of LOD per 1000 LB in-
creases from 0.17 (95 % CI: 0.10–0.30) to 0.39 (95 % CI:
0.19–0.81) highlighting the complexity of assumptions
underlying LOD incidence calculation.
This study showed the potential for high case fatality
with GBS (7–40 % by center). The high CFR reported in
Dominican Republic may have been driven by it being a
tertiary center with high rates of preterm birth [23], as
mortality was 29 % among preterm infants with GBS
compared with 16 % among term infants with GBS.
Meningitis may have been a key clinical factor associated
with the high CFR reported among LOD cases in Do-
minican Republic, where 10 of 12 LOD cases presented
with meningitis. This association of meningitis and fatal-
ity with invasive GBS disease, possibly as a result of in-
fection with the highly virulent ST-17 type III clone, is
in line with previous observations [13, 28, 29].
Overall 91 % of GBS disease cases were attributed to se-
rotypes Ia, Ib and III, highlighting the potential impact of
a vaccine targeting these serotypes. Future studies should
also consider antibiotic resistance profiling of GBS isolates
to obtain a clearer understanding of the relative impact of
different interventions, including both screening and IAP,
as well as a vaccine and immunization strategies.
Conclusions
This study confirms the importance of GBS as a pathogen
in young infants, but with considerable variation in inci-
dence and CFR across countries. The study was not de-
signed to assess the impact of differences in healthcare
access, clinical practice, specimen processing, antibiotic
usage or population differences. However, all centers
reporting invasive GBS reported a preponderance of dis-
ease in the first two days of life emphasizing the import-
ance of active surveillance within the newborn population.
The reported incidence rates emphasize the need to per-
form larger observational studies with standardized meth-
odologies for case ascertainment, laboratory analyses and
clinical follow up to determine IAP and antibiotic use
across a broad range of healthcare facilities, urban and
rural, in different regions and countries.
Competing interests
IRB, JMC, MCC and KSS are employees of Novartis Vaccines (now
GlaxoSmithKline Vaccines). LR, XSL, JFI, MI, SS, PVA and SAM are affiliated
with institutions that received grant support from Novartis Vaccines. JFI and
SAM received travel-support to attend an expert-panel group on GBS.
Authors’ contributions
IRB, JMC and KSS contributed to the conception and design of the study. LR,
XSL, JFI, MI, SS, PVA and SAM contributed to data collection and study
conduct. MCC contributed to data analysis. All authors participated in the
interpretation of the data and drafting of the manuscript. All authors read




GBS study team at Novartis: Dr. Hans Bock, Rachel Gan, Yanjun Kong, Rakha J
(International) and Ana Villarreal, Gemma Garcia, Dr. Rosalba Candelario, Dr.
Victor Sales (North of Latin America). Study co-investigators at the Hong Kong
site: Dr. Simon Lam and Prof. EAS Nelson (Department of Pediatrics), Prof.
Rivera et al. BMC Pediatrics  (2015) 15:143 Page 8 of 9
WH Tam (Department of Obstetrics and Gynecology, Chinese University of
Hong Kong), Dr. Kitty Fung (Department of Pathology, United Christian
Hospital, Hong Kong). Data collection for Dominican Republic: Dr. Josefina
Fernandez and Dr. Jacqueline Sanchez (Hospital Infantil), Dr. Robert Reid, Dr.
Sonia Mazara (Hospital Maternidad Nuestra Señora de la Altagracia). Data
collection for Bangladesh: Dr. Shams El Arifeen (Child Health Unit, Public
Health Services Division, International Center for Diarrheal Diseases Research,
Bangladesh). Medical writing services: Dr. Linda Gibbs (Business & Decision
Life Sciences, Belgium) and Keith Veitch (keithveitch communications,
Amsterdam, Netherlands).
This study sponsor was Novartis Vaccines. The sponsor was involved in all
stages of the study, including study design, data analysis and report writing.
The corresponding author had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
Author details
1Hospital Maternidad Nuestra Señora de la Altagracia, Santo Domingo,
Dominican Republic. 2Hospital del Niño and the School of Medicine of the
University of Panama, Panama City, Panama. 3Hospital Infantil Dr. Robert Reid
Cabral, Santo Domingo, República Dominicana. 4Department of
Microbiology, Chinese University of Hong Kong, Hong Kong, SAR, China.
5Department of Microbiology, Bangladesh Institute of Child Health, Dhaka
Shishu Hospital, Dhaka, Bangladesh. 6Medical Research Council Respiratory
and Meningeal Pathogens Research Unit, University of the Witwatersrand,
Johannesburg, South Africa. 7National Institute for Communicable Diseases,
Sandringham, South Africa. 8Novartis Vaccines and Diagnostics Inc.,
Cambridge, MA, USA. 9Global Development, Novartis Vaccines and
Diagnostics, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR, UK.
Received: 16 May 2014 Accepted: 22 September 2015
References
1. Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni TL, Tighe H, et al.
Group B streptococcal disease in UK and Irish infants younger than 90 days.
Lancet. 2004;363:292–4.
2. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AK, Cousens S, et al.
Group B streptococcal disease in infants aged younger than 3 months:
systematic review and meta-analysis. Lancet. 2012;379:547–56.
3. Dagnew AF, Cunnington MC, Dube Q, Edwards MS, French N, Heyderman RS,
et al. Variation in reported neonatal group B streptococcal disease incidence in
developing countries. Clin Infect Dis. 2012;55:91–102.
4. Stoll BJ, Schuchat A. Maternal carriage of group B streptococci in developing
countries. Pediatr Infect Dis J. 1998;17:499–503.
5. Schrag SJ, Zywicki S, Farley M, Reingold AL, Harrison LH, Lefkowitz LB, et al.
Group B streptococcal disease in the era of intrapartum antibiotic
prophylaxis. New Engl J Med. 2000;342:15–20.
6. Schrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig AS, et al. A
population-based comparison of strategies to prevent early-onset group B
streptococcal disease in neonates. N Engl J Med. 2002;347:233–9.
7. Stoll BJ, Hansen NI, Sánchez PJ, Faix RG, Poindexter BB, Van Meurs KP, et al.
Early onset neonatal sepsis: the burden of Group B streptococcal and E. coli
disease continues. Pediatrics. 2011;127:817–26.
8. Schrag SJ, Group B. Streptococcal vaccine for resource-poor countries.
Lancet. 2011;378:11–2.
9. Healy CM. Vaccines in pregnant women and research initiatives. Clin Obstet
Gynecol. 2012;55:474–86.
10. Darmstadt GL, Saha SK, Choi Y, El Arifeen S, Ahmed NU, Bari S, et al.
Bangladesh Projahnmo-2 (Mirzapur) Study Group. Population-based
incidence and etiology of community-acquired neonatal bacteremia in
Mirzapur, Bangladesh: an observational study. J Infect Dis. 2009;200:906–15.
11. Afshar B, Broughton K, Creti R, Decheva A, Hufnagel M, Kriz P, et al.
Members of the DEVANI Study Group, Efstratiou A. International external
quality assurance for laboratory identification and typing of Streptococcus
agalactiae (Group B streptococci). JClin Microbiol. 2011;49:1475–82.
12. Fleiss JL. Statistical methods for rates and proportions. New York: John Riley;
1981. p. 14–5.
13. Madhi SA, Radebe K, Crewe-Brown H, Frasch CE, Arakere G, Mokhachane M,
et al. High burden of invasive Streptococcus agalactiae disease in South
African infants. Ann Trop Paediatr. 2003;23:15–23.
14. Cutland CL, Madhi SA, Zell ER, Kuwanda L, Laque M, Groome M, et al.
Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and
vertical transmission of pathogenic bacteria in South Africa: a randomised,
controlled trial. Lancet. 2009;374:1909–16.
15. Verani JR, McGee L, Schrag SJ. Division of Bacterial Diseases, National Center
for Immunization and Respiratory Diseases, Centers for Disease Control and
Prevention (CDC). Prevention of perinatal group B streptococcal disease–
revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1–36.
16. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the
United States, 1990: report from a multistate active surveillance system.
MMWR CDC Surveill Summ. 1992;41:25–32.
17. Fernandez J, Sanchez J, Feris JM, Gómez E, Serulle Y, Demorizi J, et al.
Prevalencia de estreptococo grupo B (EGB) en embarazadas dominicanas.
Rev Panam Infectol. 2006;8:26–32.
18. Chan GJ, Modak JK, Mahmud AA, Baqui AH, Black RE, Saha SK. Maternal and
neonatal colonization in Bangladesh: prevalence, etiologies and risk factors.
J Perinatol. 2013;33:971–6.
19. Tsui MH, Ip M, Ng PC, Sahota DS, Leung TN, Lau TK. Change in prevalence
of Group B Streptococcus maternal colonization in Hong Kong. Hong Kong
Med J. 2009;15:414–9.
20. Anon. Disparities in universal prenatal screening for group B streptococcus–
North Carolina, 2002–2003. Morb Mortal Wkly Rep. 2005;54:700–3.
21. Anon. Trends in perinatal group B streptococcal disease — United States,
2000—2006. Morb Mortal Wkly Rep. 2009;58:109–12.
22. Regan JA, Klebanoff MA, Nugent RP. The epidemiology of group B
streptococcal colonization in pregnancy. Obstet Gynecol. 1991;77:604–10.
23. Weston EJ, Pondo T, Lewis MM, Martell-Cleary P, Morin C, Jewell B, et al. The
burden of invasive early-onset neonatal sepsis in the United States,
2005–2008. Pediatr Infect Dis J. 2011;30:937–41.
24. Zhaidi AKM, Thaver D, Asad S, Khan TA. Pathogens associated with sepsis in
newborns and young infants in developing countries. Pediatr Infect Dis J.
2009;28:S10–8.
25. Weinstein MP. Blood culture contamination: persisting problems and partial
progress. J Clin Microbiol. 2003;41:2275–8.
26. Lakshmi V. Culture of body fluids using the bact/alert system. Indian J Med
Microbiol. 2001;19:44–50.
27. Choudhury N, Moran AC, Alam MA, Ahsan KZ, Rashid SF, Streatfield PK.
Beliefs and practices during pregnancy and childbirth in urban slums of
Dhaka, Bangladesh. BMC Public Health. 2012;12:791.
28. Jones N, Bohnsack JF, Takahashi S, Oliver KA, Chan MS, Kunst F, et al.
Multilocus sequence typing system for group B streptococcus. J Clin
Microbiol. 2003;41:e2530–6.
29. Luan SL, Granlund M, Sellin M, Lagergard T, Spratt BG, Norgren M.
Multilocus sequence typing of Swedish invasive group B streptococcus
isolates indicates a neonatally associated genetic lineage and capsule
switching. J Clin Microbiol. 2005;43:e3727–33.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rivera et al. BMC Pediatrics  (2015) 15:143 Page 9 of 9
